Advertisement

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids

Published:November 03, 2017DOI:https://doi.org/10.1016/j.plefa.2017.10.006

      Abstract

      Metabolic syndrome (MetSyn) is characterized by chronic inflammation which mediates the associated high risk for cardiovascular and other diseases. Oxylipins are a superclass of lipid mediators with potent bioactivities in inflammation, vascular biology, and more. While their role as locally produced agents is appreciated, most oxylipins in plasma are found in lipoproteins suggesting defective regulation of inflammation could be mediated by the elevated VLDL and low HDL levels characteristic of MetSyn. Our objective was to compare the oxylipin composition of VLDL, LDL, and HDL in 14 optimally healthy individuals and 31 MetSyn patients, and then to determine the effects of treating MetSyn subjects with 4 g/day of prescription omega-3 fatty acids (P-OM3) on lipoprotein oxylipin profiles. We compared oxylipin compositions of healthy (14) and MetSyn (31) subjects followed by randomization and assignment to 4 g/d P-OM3 for 16 weeks using LC/MS/MS. Compared to healthy subjects, MetSyn is characterized by abnormalities of (1) pro-inflammatory, arachidonate-derived oxylipins from the lipoxygenase pathway in HDL; and (2) oxylipins mostly not derived from arachidonate in VLDL. P-OM3 treatment corrected many components of these abnormalities, reducing the burden of inflammatory mediators within peripherally circulating lipoproteins that could interfere with, or enhance, local effectors of inflammatory stress. We conclude that MetSyn is associated with a disruption of lipoprotein oxylipin patterns consistent with greater inflammatory stress, and the partial correction of these dysoxylipinemias by treatment with omega-3 fatty acids could explain some of their beneficial effects.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III), JAMA, 285, 2001, pp. 2486–2497.

        • Lakka H.M.
        • Laaksonen D.E.
        • Lakka T.A.
        • Niskanen L.K.
        • Kumpusalo E.
        • Tuomilehto J.
        • Salonen J.T.
        The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
        J. Am. Med. Assoc. 2002; 288: 2709-2716
        • Kinsell L.W.
        • Michaels G.D.
        • Walker G.
        • Visintine R.E.
        The effect of a fish-oil fraction on plasma lipids.
        Diabetes. 1961; 10: 316-319
        • Harris W.S.
        • Ginsberg H.N.
        • Arunakul N.
        • Shachter N.S.
        • Windsor S.L.
        • Adams M.
        • Berglund L.
        • Osmundsen K.
        Safety and efficacy of Omacor in severe hypertriglyceridemia.
        J. Cardiovasc. Risk. 1997; 4: 385-391
        • Davidson M.H.
        • Stein E.A.
        • Bays H.E.
        • Maki K.C.
        • Doyle R.T.
        • Shalwitz R.A.
        • Ballantyne C.M.
        • Ginsberg H.N.
        Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
        Clin. Ther. 2007; 29: 1354-1367
        • Yokoyama M.
        • Origasa H.
        • Matsuzaki M.
        • Matsuzawa Y.
        • Saito Y.
        • Ishikawa Y.
        • Oikawa S.
        • Sasaki J.
        • Hishida H.
        • Itakura H.
        • Kita T.
        • Kitabatake A.
        • Nakaya N.
        • Sakata T.
        • Shimada K.
        • Shirato K.
        Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
        Lancet. 2007; 369: 1090-1098
        • Bittner V.
        • Johnson B.D.
        • Zineh I.
        • Rogers W.J.
        • Vido D.
        • Marroquin O.C.
        • Bairey-Merz C.N.
        • Sopko G.
        The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE).
        Am. Heart J. 2009; 157: 548-555
        • Assmann G.
        • Schulte H.
        • Cullen P.
        • Seedorf U.
        Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study.
        Eur. J. Clin. Investig. 2007; 37: 925-932
        • Shearer G.C.
        • Harris W.S.
        • Pedersen T.L.
        • Newman J.W.
        , Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters.
        J. Lipid Res. 2010; 51: 2074-2081
        • Keenan A.H.
        • Pedersen T.L.
        • Fillaus K.
        • Larson M.K.
        • Shearer G.C.
        • Newman J.W.
        Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers.
        J. Lipid Res. 2012;
        • Block R.C.
        • Duff R.
        • Lawrence P.
        • Kakinami L.
        • Brenna J.T.
        • Shearer G.C.
        • Meednu N.
        • Mousa S.
        • Friedman A.
        • Harris W.S.
        • Larson M.
        • Georas S.
        The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin.
        Prostaglandins Leukot. Essent. Fat. Acids. 2010; 82: 87-95
        • Shearer G.C.
        • Newman J.W.
        Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins.
        Prostaglandins Leukot. Essent. Fat. Acids. 2008; 79: 215-222
        • Newman J.W.
        • Pedersen T.L.
        • Brandenburg V.R.
        • Harris W.S.
        • Shearer G.C.
        Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects.
        PLoS One. 2014; 9: e111471
        • Shearer G.C.
        • Pottala J.V.
        • Hansen S.N.
        • Brandenburg V.
        • Harris W.S.
        Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial.
        J. Lipid Res. 2012; 53: 2429-2435
        • Savinova O.V.
        • Fillaus K.
        • Jing L.
        • Harris W.S.
        • Shearer G.C.
        Reduced apolipoprotein glycosylation in patients with the metabolic syndrome.
        PLoS One. 2014; 9: e104833
        • Savinova O.V.
        • Fillaus K.
        • Harris W.S.
        • Shearer G.C.
        Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
        Atherosclerosis. 2015; 240: 520-525
        • Harris W.S.
        • Von Schacky C.
        The Omega-3 Index: a new risk factor for death from coronary heart disease?.
        Prev. Med. 2004; 39: 212-220
        • Newman J.W.
        • Kaysen G.A.
        • Hammock B.D.
        • Shearer G.C.
        Proteinuria increases oxylipid concentrations in VLDL and HDL, but not LDL particles in the rat.
        J. Lipid Res. 2007;
        • Luria A.
        • Weldon S.M.
        • Kabcenell A.K.
        • Ingraham R.H.
        • Matera D.
        • Jiang H.
        • Gill R.
        • Morisseau C.
        • Newman J.W.
        • Hammock B.D.
        Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice.
        J. Biol. Chem. 2007; 282: 2891-2898
        • Fang X.
        • Weintraub N.L.
        • Stoll L.L.
        • Spector A.A.
        Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells.
        Hypertension. 1999; 34: 1242-1246
        • Johnson W.E.
        • Li C.
        • Rabinovic A.
        Adjusting batch effects in microarray expression data using empirical Bayes methods.
        Biostatistics. 2007; 8: 118-127
      2. J.T. Leek, W.E. Johnson, H.S. Parker, A.E. Jaffe, J.D. Storey, sva:Surrogate Variable Analysis, in, 2011.

        • Langfelder P.
        • Horvath S.
        WGCNA: an R package for weighted correlation network analysis.
        BMC Bioinform. 2008; 9: 559
        • Chen J.
        • Shearer G.C.
        • Chen Q.
        • Healy C.L.
        • Beyer A.J.
        • Nareddy V.B.
        • Gerdes A.M.
        • Harris W.S.
        • O'Connell T.D.
        • Wang D.
        Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts.
        Circulation. 2011; 123: 584-593
        • Gentleman R.C.
        • Carey V.J.
        • Bates D.M.
        • Bolstad B.
        • Dettling M.
        • Dudoit S.
        • Ellis B.
        • Gautier L.
        • Ge Y.
        • Gentry J.
        • Hornik K.
        • Hothorn T.
        • Huber W.
        • Iacus S.
        • Irizarry R.
        • Leisch F.
        • Li C.
        • Maechler M.
        • Rossini A.J.
        • Sawitzki G.
        • Smith C.
        • Smyth G.
        • Tierney L.
        • Yang J.Y.
        • Zhang J.
        Bioconductor: open software development for computational biology and bioinformatics.
        Genome Biol. 2004; 5: R80
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • Donato K.A.
        • Eckel R.H.
        • Franklin B.A.
        • Gordon D.J.
        • Krauss R.M.
        • Savage P.J.
        • Smith Jr., S.C.
        • Spertus J.A.
        • Costa F.
        • A. American Heart, L. National Heart, I. Blood
        Diagnosis and management of the metabolic syndrome: an american heart association/national heart, lung, and blood institute scientific statement.
        Circulation. 2005; 112: 2735-2752
        • Augustine A.H.
        • Lowenstein L.M.
        • Harris W.S.
        • Shearer G.C.
        • Block R.C.
        Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance.
        Prostaglandins Leukot. Essent. Fat. Acids. 2014; 90: 69-75
        • Newman J.W.
        • Kaysen G.A.
        • Hammock B.D.
        • Shearer G.C.
        Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat.
        J. Lipid Res. 2007; 48: 1792-1800
        • Wang L.
        • Gill R.
        • Pedersen T.L.
        • Higgins L.J.
        • Newman J.W.
        • Rutledge J.C.
        Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.
        J. Lipid Res. 2009; 50: 204-213
        • Ruby M.A.
        • Goldenson B.
        • Orasanu G.
        • Johnston T.P.
        • Plutzky J.
        • Krauss R.M.
        VLDL hydrolysis by LPL activates PPAR-alpha through generation of unbound fatty acids.
        J. Lipid Res. 2010; 51: 2275-2281
        • Ziouzenkova O.
        • Perrey S.
        • Asatryan L.
        • Hwang J.
        • MacNaul K.L.
        • Moller D.E.
        • Rader D.J.
        • Sevanian A.
        • Zechner R.
        • Hoefler G.
        • Plutzky J.
        Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase.
        Proc. Natl. Acad. Sci. USA. 2003; 100: 2730-2735
        • Brown J.D.
        • Oligino E.
        • Rader D.J.
        • Saghatelian A.
        • Plutzky J.
        VLDL hydrolysis by hepatic lipase regulates PPARdelta transcriptional responses.
        PLoS One. 2011; 6: e21209
        • Ahmed W.
        • Orasanu G.
        • Nehra V.
        • Asatryan L.
        • Rader D.J.
        • Ziouzenkova O.
        • Plutzky J.
        High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.
        Circ. Res. 2006; 98: 490-498
        • Itoh T.
        • Fairall L.
        • Amin K.
        • Inaba Y.
        • Szanto A.
        • Balint B.L.
        • Nagy L.
        • Yamamoto K.
        • Schwabe J.W.
        Structural basis for the activation of PPARgamma by oxidized fatty acids.
        Nat. Struct. Mol. Biol. 2008; 15: 924-931
        • Hersberger M.
        • von Eckardstein A.
        Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
        Drugs. 2003; 63: 1907-1945
        • Dichtl W.
        • Nilsson L.
        • Goncalves I.
        • Ares M.P.
        • Banfi C.
        • Calara F.
        • Hamsten A.
        • Eriksson P.
        • Nilsson J.
        Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells.
        Circ. Res. 1999; 84: 1085-1094
        • Ting H.J.
        • Stice J.P.
        • Schaff U.Y.
        • Hui D.Y.
        • Rutledge J.C.
        • Knowlton A.A.
        • Passerini A.G.
        • Simon S.I.
        Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha.
        Circ. Res. 2007; 100: 381-390
        • Tschernatsch M.M.
        • Mlecnik B.
        • Trajanoski Z.
        • Zechner R.
        • Zimmermann R.
        LPL-mediated lipolysis of VLDL induces an upregulation of AU-rich mRNAs and an activation of HuR in endothelial cells.
        Atherosclerosis. 2006; 189: 310-317
        • Campbell W.B.
        • Gebremedhin D.
        • Pratt P.F.
        • Harder D.R.
        Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.
        Circ. Res. 1996; 78: 415-423
        • Hu S.
        • Kim H.S.
        Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid.
        Eur. J. Pharmacol. 1993; 230: 215-221
        • Vriens J.
        • Owsianik G.
        • Fisslthaler B.
        • Suzuki M.
        • Janssens A.
        • Voets T.
        • Morisseau C.
        • Hammock B.D.
        • Fleming I.
        • Busse R.
        • Nilius B.
        Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium.
        Circ. Res. 2005; 97: 908-915
        • Fornoni A.
        • Raij L.
        Metabolic syndrome and endothelial dysfunction.
        Curr. Hypertens. Rep. 2005; 7: 88-95
        • Schwab J.M.
        • Serhan C.N.
        Lipoxins and new lipid mediators in the resolution of inflammation.
        Curr. Opin. Pharmacol. 2006; 6: 414-420
        • Whatling C.
        • McPheat W.
        • Herslof M.
        The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
        Expert Opin. Investig. Drugs. 2007; 16: 1879-1893
        • Lazarus S.C.
        • Lee T.
        • Kemp J.P.
        • Wenzel S.
        • Dube L.M.
        • Ochs R.F.
        • Carpentier P.J.
        • Lancaster J.F.
        Safety and clinical efficacy of zileuton in patients with chronic asthma.
        Am. J. Manag. Care. 1998; 4: 841-848
        • Pallast S.
        • Arai K.
        • Pekcec A.
        • Yigitkanli K.
        • Yu Z.
        • Wang X.
        • Lo E.H.
        • van Leyen K.
        Increased nuclear apoptosis-inducing factor after transient focal ischemia: a 12/15-lipoxygenase-dependent organelle damage pathway.
        J. Cereb. Blood Flow Metab. 2010; 30: 1157-1167
        • Serhan C.N.
        Pro-resolving lipid mediators are leads for resolution physiology.
        Nature. 2014; 510: 92-101
        • Wittwer J.
        • Hersberger M.
        The two faces of the 15-lipoxygenase in atherosclerosis.
        Prostaglandins Leukot. Essent. Fat. Acids. 2007; 77: 67-77
        • Gertow K.
        • Nobili E.
        • Folkersen L.
        • Newman J.W.
        • Pedersen T.L.
        • Ekstrand J.
        • Swedenborg J.
        • Kuhn H.
        • Wheelock C.E.
        • Hansson G.K.
        • Hedin U.
        • Haeggstrom J.Z.
        • Gabrielsen A.
        12- and 15-lipoxygenases in human carotid atherosclerotic lesions: associations with cerebrovascular symptoms.
        Atherosclerosis. 2011; 215: 411-416
        • Grant G.E.
        • Rokach J.
        • Powell W.S.
        5-Oxo-ETE and the OXE receptor.
        Prostaglandins Other Lipid Mediat. 2009; 89: 98-104
        • De Felice C.
        • Signorini C.
        • Durand T.
        • Ciccoli L.
        • Leoncini S.
        • D'Esposito M.
        • Filosa S.
        • Oger C.
        • Guy A.
        • Bultel-Ponce V.
        • Galano J.M.
        • Pecorelli A.
        • De Felice L.
        • Valacchi G.
        • Hayek J.
        Partial rescue of Rett syndrome by omega-3 polyunsaturated fatty acids (PUFAs) oil.
        Genes Nutr. 2012; 7: 447-458
        • Borja M.S.
        • Hammerson B.
        • Tang C.
        • Savinova O.V.
        • Shearer G.C.
        • Oda M.N.
        Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease.
        PLoS One. 2017; 12: e0182217

      CHORUS Manuscript

      View Open Manuscript